extract: 2025-03-17-norc-pace-market-assessment-for-profit-expansion

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md

@@ -27,6 +27,12 @@ This is not an American problem alone. The American diet and lifestyle are sprea
 
 The four major risk factors behind the highest burden of noncommunicable disease -- tobacco use, harmful use of alcohol, unhealthy diets, and physical inactivity -- are all lifestyle factors that simple interventions could address. The gap between what science knows works (lifestyle modification) and what the system delivers (pharmaceutical symptom management) represents one of the largest misalignments in the modern economy.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+
+GLP-1s may function as a pharmacological counter to engineered food addiction. The population-level obesity decline (39.9% to 37.0%) coinciding with 12.4% adult GLP-1 adoption suggests pharmaceutical intervention can partially offset the metabolic consequences of engineered hyperpalatable foods, though this addresses symptoms rather than root causes of the food environment.
+
 ---
 
 Relevant Notes:

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -23,6 +23,12 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric
 
 Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+
+The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category.
+
 ---
 
 Relevant Notes:

domains/health/pace-demonstrates-integrated-care-averts-institutionalization-through-community-based-delivery-not-cost-reduction.md

@@ -34,7 +34,7 @@ Some evidence indicates lower mortality rates among PACE enrollees, suggesting q
 
 
 ### Additional Evidence (extend)
-*Source: 2021-02-00-pmc-japan-ltci-past-present-future | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: [[2021-02-00-pmc-japan-ltci-past-present-future]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
 
 Japan's LTCI provides a national-scale comparison point for PACE's integrated care model. LTCI offers both facility-based and home-based care chosen by beneficiaries, integrating medical care with welfare services across 7 care level tiers. As of 2015, the system served 5+ million beneficiaries (17% of 65+ population) — compared to PACE's 90,000 enrollees in the US. If the US had equivalent coverage, that would represent ~11.4 million people. Japan's experience demonstrates that integrated care delivery can operate at national scale through mandatory insurance, though financial sustainability under extreme aging demographics (28.4% elderly, rising to 40%) remains an ongoing challenge requiring premium and copayment adjustments.
 
@@ -42,7 +42,7 @@ Japan's LTCI provides a national-scale comparison point for PACE's integrated ca
 ### Additional Evidence (extend)
 *Source: [[2025-03-17-norc-pace-market-assessment-for-profit-expansion]] | Added: 2026-03-15*
 
-NORC 2025 report confirms PACE serves average age 76, 7+ chronic conditions, nursing-home eligible population—the most complex, costly Medicare-Medicaid beneficiaries. This is the population MA plans are least equipped to serve profitably, making PACE the existence proof that full capitation works for high-complexity cases. The 12% annual growth in 2025 (reaching 90,580 enrollees) is faster than recent years, suggesting potential inflection despite 50-year 0.13% penetration rate.
+NORC 2025 report provides updated enrollment data: 90,580 enrollees as of end-2025 (12% annual growth), 198 programs in 33 states + DC, serving members averaging 76 years old with 7+ chronic conditions. Geographic concentration shows over 50% of enrollees in just 3 states (CA, NY, PA), with only 13 states having 1,000+ enrollees. Market concentration shows nearly half of all enrollees served by 10 largest parent organizations, while most operators run single programs in one state.
 
 ---
 
@@ -52,4 +52,4 @@ Relevant Notes:
 - [[social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem]]
 
 Topics:
-- health/_map
+- [[health/_map]]

domains/health/the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations.md

@@ -31,6 +31,12 @@ Since specialization and value form an autocatalytic feedback loop where each am
 
 The Commonwealth Fund's 2024 international comparison demonstrates this transition empirically across 10 developed nations. All countries compared (Australia, Canada, France, Germany, Netherlands, New Zealand, Sweden, Switzerland, UK, US) have eliminated material scarcity in healthcare — all possess advanced clinical capabilities and universal or near-universal access infrastructure. Yet health outcomes vary dramatically. The US spends >16% of GDP (highest by far) with worst outcomes, while top performers (Australia, Netherlands) spend the lowest percentage of GDP. The differentiator is not clinical capability (US ranks 2nd in care process quality) but access structures and equity — social determinants. This proves that among developed nations with sufficient material resources, social disadvantage (who gets care, discrimination, equity barriers) drives outcomes more powerfully than clinical quality or spending volume.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+
+GLP-1 access inequality demonstrates the epidemiological transition in action: the intervention addresses metabolic disease (post-transition health problem) but access stratifies by wealth and insurance status (social disadvantage), potentially widening health inequalities even as population-level outcomes improve. The WHO's emphasis on 'multisectoral action' and 'healthier environments' acknowledges that pharmaceutical solutions alone cannot address socially-determined health outcomes.
+
 ---
 
 Relevant Notes:

domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md

@@ -287,7 +287,7 @@ PACE provides the most comprehensive real-world test of the prevention-first att
 
 
 ### Additional Evidence (extend)
-*Source: 2024-09-19-commonwealth-fund-mirror-mirror-2024 | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: [[2024-09-19-commonwealth-fund-mirror-mirror-2024]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
 The Commonwealth Fund's 2024 international comparison provides evidence that the prevention-first attractor state is not theoretical — peer nations demonstrate it empirically. The top performers (Australia, Netherlands) achieve better health outcomes with lower spending as percentage of GDP, suggesting their systems have structural features that prevent rather than treat. The US paradox (2nd in care process, last in outcomes, highest spending, lowest efficiency) reveals a system optimized for treating sickness rather than producing health. The efficiency domain rankings (US among worst — highest spending, lowest return) quantify the cost of a sick-care attractor state. The international benchmark shows that systems with better access, equity, and prevention orientation achieve superior outcomes at lower cost, suggesting the prevention-first attractor state is achievable and economically superior to the current US sick-care model.
 
@@ -295,7 +295,7 @@ The Commonwealth Fund's 2024 international comparison provides evidence that the
 ### Additional Evidence (challenge)
 *Source: [[2025-03-17-norc-pace-market-assessment-for-profit-expansion]] | Added: 2026-03-15*
 
-PACE represents the attractor state's core elements (full capitation, integrated care, single provider-payer) but has achieved only 0.13% Medicare penetration after 50 years. Seven structural barriers prevent scaling: capital requirements, awareness deficits, insufficient enrollee concentration, geographic concentration, financial eligibility barriers, regulatory complexity, and single-state operator limitations. This suggests the attractor state may be theoretically correct but practically unreachable under current conditions—the gap between model elegance and market reality is enormous.
+PACE is the strongest existence proof that full capitation works for complex patients (76 years old, 7+ chronic conditions, nursing-home eligible), yet it has failed to scale beyond 0.13% Medicare penetration after 50 years. If the attractor state is real and self-reinforcing, PACE should be the fastest-growing model—it has perfect payment alignment, full integration, and proven clinical outcomes. Instead, it remains a niche serving 90,580 people while MA serves 36M+. This suggests the attractor state faces structural barriers (capital intensity, awareness deficits, regulatory complexity, geographic concentration) that prevent the flywheel from spinning even when all components are present.
 
 ---
 

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -19,13 +19,13 @@ The Making Care Primary model's termination in June 2025 (after just 12 months,
 
 
 ### Additional Evidence (extend)
-*Source: 2014-00-00-aspe-pace-effect-costs-nursing-home-mortality | Added: 2026-03-10 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: [[2014-00-00-aspe-pace-effect-costs-nursing-home-mortality]] | Added: 2026-03-10 | Extractor: anthropic/claude-sonnet-4.5*
 
 PACE represents the extreme end of value-based care alignment—100% capitation with full financial risk for a nursing-home-eligible population. The ASPE/HHS evaluation shows that even under complete payment alignment, PACE does not reduce total costs but redistributes them (lower Medicare acute costs in early months, higher Medicaid chronic costs overall). This suggests that the 'payment boundary' stall may not be primarily a problem of insufficient risk-bearing. Rather, the economic case for value-based care may rest on quality/preference improvements rather than cost reduction. PACE's 'stall' is not at the payment boundary—it's at the cost-savings promise. The implication: value-based care may require a different success metric (outcome quality, institutionalization avoidance, mortality reduction) than the current cost-reduction narrative assumes.
 
 
 ### Additional Evidence (extend)
-*Source: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
 
 GLP-1 persistence data illustrates why value-based care requires risk alignment: with only 32.3% of non-diabetic obesity patients remaining on GLP-1s at one year (15% at two years), the downstream savings that justify the upfront drug cost never materialize for 85% of patients. Under fee-for-service, the pharmacy benefit pays the cost but doesn't capture the avoided hospitalizations. Under partial risk (upside-only), providers have no incentive to invest in adherence support because they don't bear the cost of discontinuation. Only under full risk (capitation) does the entity paying for the drug also capture the downstream savings—but only if adherence is sustained. This makes GLP-1 economics a test case for whether value-based care can solve the "who pays vs. who benefits" misalignment.
 
@@ -33,7 +33,7 @@ GLP-1 persistence data illustrates why value-based care requires risk alignment:
 ### Additional Evidence (confirm)
 *Source: [[2025-03-17-norc-pace-market-assessment-for-profit-expansion]] | Added: 2026-03-15*
 
-PACE is the most fully integrated capitated model in existence—100% of member's medical, social, and psychiatric needs under single provider-payer, entirely replacing Medicare and Medicaid cards. Yet after 50 years it serves only 90K of 67M Medicare-eligible (0.13% penetration). This confirms that even proven full-risk models face structural barriers to scaling, supporting the claim that VBC stalls at the payment boundary despite model success.
+PACE represents the extreme case of full risk—100% capitation for all medical, social, and psychiatric needs—yet after 50 years achieves only 0.13% Medicare penetration (90,580 enrollees out of 67M eligible). This confirms that even when payment alignment is complete, structural barriers (capital requirements, awareness, regulatory complexity, geographic concentration) prevent scaling. The gap between PACE's 0.13% and MA's 54% penetration demonstrates that partial risk models scale 415x faster than full risk models despite weaker incentive alignment.
 
 ---
 

domains/internet-finance/MetaDAOs Autocrat program implements futarchy through conditional token markets where proposals create parallel pass and fail universes settled by time-weighted average price over a three-day window.md

@@ -77,6 +77,12 @@ Autocrat v0.1 made the three-day window configurable rather than hardcoded, with
 
 Proposal #3 on MetaDAO (account EXehk1u3qUJZSxJ4X3nHsiTocRhzwq3eQAa6WKxeJ8Xs) ran on Autocrat version 0.3, created 2024-07-04, and completed/ended 2024-07-08 - confirming the four-day operational window (proposal creation plus three-day settlement period) specified in the mechanism design.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-03-05-futardio-proposal-proposal-1]] | Added: 2026-03-15*
+
+Production deployment data from futard.io shows Proposal #1 on DAO account De8YzDKudqgeJXqq6i7q82AgxxrQ1JXXfMgouQuPyhY using Autocrat version 0.3, with proposal created, ended, and completed all on 2025-03-05. This confirms operational use of the Autocrat v0.3 implementation in live governance.
+
 ---
 
 Relevant Notes:

entities/entertainment/beast-industries.md

@@ -29,5 +29,7 @@ Beast Industries is MrBeast's (Jimmy Donaldson) integrated media and consumer pr
 - **2025** — Feastables generated $250M revenue with $20M+ profit; media business similar revenue but ~$80M loss
 - **2025** — Feastables distributed through 30,000+ retail locations (Walmart, Target, 7-Eleven)
 
+- **2024** — Media business (YouTube + Amazon Prime) lost $80M while Feastables generated $250M revenue with $20M+ profit; Feastables available in 30,000+ retail locations (Walmart, Target, 7-Eleven) across US, Canada, Mexico
+- **2025-03-10** — Raising capital at $5B valuation; projecting $899M total revenue (2025), $1.6B (2026), $4.78B (2029); Feastables projected $520M (2025) vs $288M media revenue; media projected to be 1/5 of total sales by 2026
 ## Relationship to KB
 Beast Industries provides enterprise-scale validation of [[the media attractor state is community-filtered IP with AI-collapsed production costs where content becomes a loss leader for the scarce complements of fandom community and ownership]]. The $5B valuation represents market pricing of the integrated content-to-product model, where media operates at a loss to generate zero marginal cost customer acquisition for high-margin CPG products.

entities/internet-finance/futardio.md

@@ -49,6 +49,7 @@ MetaDAO's token launch platform. Implements "unruggable ICOs" — permissionless
 - **2026-03-05** — [[insert-coin-labs-futardio-fundraise]] launched for Web3 gaming studio (failed, $2,508 / $50K = 5% of target)
 - **2026-03-05** — [[git3-futardio-fundraise]] failed: Git3 raised $28,266 of $100K target (28.3%) before entering refunding status, demonstrating market filtering even with live MVP
 - **2024-06-14** — [[futardio-fund-rug-bounty-program]] passed: Approved $5K USDC funding for RugBounty.xyz platform development to incentivize community recovery from rug pulls
+- **2024-08-28** — MetaDAO proposal to develop futardio as memecoin launchpad with futarchy governance failed. Proposal would have allocated $100k grant over 6 months to development team. Key features: percentage of each new token supply allocated to futarchy DAO, points-to-token conversion within 180 days, revenue distribution to $FUTA holders, immutable deployment on IPFS/Arweave. Proposal rejected by market, suggesting reputational risks outweighed adoption benefits.
 ## Competitive Position
 - **Unique mechanism**: Only launch platform with futarchy-governed accountability and treasury return guarantees
 - **vs pump.fun**: pump.fun is memecoin launch (zero accountability, pure speculation). Futardio is ownership coin launch (futarchy governance, treasury enforcement). Different categories despite both being "launch platforms."

inbox/archive/.extraction-debug/2025-03-17-norc-pace-market-assessment-for-profit-expansion.json

@@ -1,7 +1,7 @@
 {
   "rejected_claims": [
     {
-      "filename": "pace-50-year-failure-to-scale-proves-structural-barriers-prevent-full-capitation-despite-model-success.md",
+      "filename": "pace-50-year-scaling-failure-reveals-structural-barriers-to-full-capitation-despite-model-success.md",
       "issues": [
         "missing_attribution_extractor"
       ]
@@ -13,7 +13,7 @@
       ]
     },
     {
-      "filename": "pace-market-concentration-in-three-states-prevents-national-model-validation-and-limits-policy-generalization.md",
+      "filename": "pace-market-concentration-in-three-states-limits-national-model-validation-and-prevents-distributed-learning.md",
       "issues": [
         "missing_attribution_extractor"
       ]
@@ -25,14 +25,14 @@
     "fixed": 3,
     "rejected": 3,
     "fixes_applied": [
-      "pace-50-year-failure-to-scale-proves-structural-barriers-prevent-full-capitation-despite-model-success.md:set_created:2026-03-15",
+      "pace-50-year-scaling-failure-reveals-structural-barriers-to-full-capitation-despite-model-success.md:set_created:2026-03-15",
       "for-profit-pace-entry-creates-scaling-inflection-through-capital-and-operational-capacity-but-risks-mission-drift.md:set_created:2026-03-15",
-      "pace-market-concentration-in-three-states-prevents-national-model-validation-and-limits-policy-generalization.md:set_created:2026-03-15"
+      "pace-market-concentration-in-three-states-limits-national-model-validation-and-prevents-distributed-learning.md:set_created:2026-03-15"
     ],
     "rejections": [
-      "pace-50-year-failure-to-scale-proves-structural-barriers-prevent-full-capitation-despite-model-success.md:missing_attribution_extractor",
+      "pace-50-year-scaling-failure-reveals-structural-barriers-to-full-capitation-despite-model-success.md:missing_attribution_extractor",
       "for-profit-pace-entry-creates-scaling-inflection-through-capital-and-operational-capacity-but-risks-mission-drift.md:missing_attribution_extractor",
-      "pace-market-concentration-in-three-states-prevents-national-model-validation-and-limits-policy-generalization.md:missing_attribution_extractor"
+      "pace-market-concentration-in-three-states-limits-national-model-validation-and-prevents-distributed-learning.md:missing_attribution_extractor"
     ]
   },
   "model": "anthropic/claude-sonnet-4.5",

inbox/archive/.extraction-debug/2025-06-01-cell-med-glp1-societal-implications-obesity.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-adoption-produced-first-measurable-population-level-obesity-decline-demonstrating-pharmaceutical-intervention-can-shift-population-health-outcomes.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "glp-1-access-inequality-risks-creating-two-tier-metabolic-health-system-where-pharmacological-prevention-stratifies-by-wealth-while-root-causes-remain-unaddressed.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "glp-1-adoption-produced-first-measurable-population-level-obesity-decline-demonstrating-pharmaceutical-intervention-can-shift-population-health-outcomes.md:set_created:2026-03-15",
+      "glp-1-access-inequality-risks-creating-two-tier-metabolic-health-system-where-pharmacological-prevention-stratifies-by-wealth-while-root-causes-remain-unaddressed.md:set_created:2026-03-15"
+    ],
+    "rejections": [
+      "glp-1-adoption-produced-first-measurable-population-level-obesity-decline-demonstrating-pharmaceutical-intervention-can-shift-population-health-outcomes.md:missing_attribution_extractor",
+      "glp-1-access-inequality-risks-creating-two-tier-metabolic-health-system-where-pharmacological-prevention-stratifies-by-wealth-while-root-causes-remain-unaddressed.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-15"
+}

inbox/archive/2025-03-05-futardio-proposal-proposal-1.md

@@ -6,7 +6,7 @@ url: "https://www.futard.io/proposal/EksJ2GhxbmhVAdDKP4kThHiuzKwjhq5HSb1kgFj6x2Q
 date: 2025-03-05
 domain: internet-finance
 format: data
-status: unprocessed
+status: enrichment
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
 processed_by: rio
@@ -14,6 +14,10 @@ processed_date: 2025-03-11
 enrichments_applied: ["MetaDAOs Autocrat program implements futarchy through conditional token markets where proposals create parallel pass and fail universes settled by time-weighted average price over a three-day window.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
 extraction_notes: "This is raw proposal data from futard.io showing a passed proposal. No project name or proposal details provided beyond metadata. The data confirms operational use of Autocrat v0.3 but contains no arguable claims or novel insights—only verifiable transaction facts. Enriches existing claim about MetaDAO's Autocrat implementation with concrete production evidence."
+processed_by: rio
+processed_date: 2026-03-15
+enrichments_applied: ["MetaDAOs Autocrat program implements futarchy through conditional token markets where proposals create parallel pass and fail universes settled by time-weighted average price over a three-day window.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Proposal Details
@@ -41,3 +45,10 @@ extraction_notes: "This is raw proposal data from futard.io showing a passed pro
 - Autocrat version: 0.3
 - Status: Passed
 - Created, ended, and completed: 2025-03-05
+
+
+## Key Facts
+- Proposal #1 on futard.io (account EksJ2GhxbmhVAdDKP4kThHiuzKwjhq5HSb1kgFj6x2Qu) passed on 2025-03-05
+- DAO account De8YzDKudqgeJXqq6i7q82AgxxrQ1JXXfMgouQuPyhY is using Autocrat version 0.3
+- Proposer account: 89VB5UmvopuCFmp5Mf8YPX28fGvvqn79afCgouQuPyhY
+- Proposal lifecycle (created, ended, completed) all occurred on same day: 2025-03-05

inbox/archive/2025-03-05-futardio-proposal-proposal-3.md

@@ -6,9 +6,12 @@ url: "https://www.futard.io/proposal/HCHkdhiPh2q9LTyvUpfyfuybPHW7qg1T2vGtiJzGPrs
 date: 2025-03-05
 domain: internet-finance
 format: data
-status: unprocessed
+status: enrichment
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
+processed_by: rio
+processed_date: 2026-03-15
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Proposal Details
@@ -27,3 +30,11 @@ event_type: proposal
 - Autocrat version: 0.3
 - Completed: 2025-03-08
 - Ended: 2025-03-08
+
+
+## Key Facts
+- Futard.io Proposal #3 (HCHkdhiPh2q9LTyvUpfyfuybPHW7qg1T2vGtiJzGPrsG) was created on 2025-03-05
+- Proposal #3 used Autocrat version 0.3
+- Proposal #3 completed and passed on 2025-03-08
+- Proposal #3 ran on DAO account 5n61x4BeVvvRMcYBMaorhu1MaZDViYw6HghE8gwLCvPR
+- Proposal #3 was submitted by proposer 89VB5UmvopuCFmp5Mf8YPX28fGvvqn79afCgouQuPyhY

inbox/archive/2025-03-17-norc-pace-market-assessment-for-profit-expansion.md

@@ -76,13 +76,14 @@ EXTRACTION HINT: The 0.13% penetration after 50 years is the key number. Compare
 
 
 ## Key Facts
-- PACE enrolled 80,815 participants on January 1, 2025, growing to 90,580 by year-end (12% annual growth)
-- 198 PACE programs operate in 33 states plus DC as of 2025
-- Over 376 PACE centers serve approximately 87,000 participants (September 2025 data)
-- Nearly half of all PACE enrollees served by 10 largest parent organizations
-- Only 13 states have 1,000+ PACE enrollees
-- Over half of PACE enrollees concentrated in California, New York, and Pennsylvania
+- PACE enrollment as of January 1, 2025: 80,815
+- PACE enrollment as of end-2025: 90,580 (12% annual growth)
+- PACE programs: 198 in 33 states + DC
+- PACE centers: 376+ serving ~87,000 participants (September 2025 data)
 - Average PACE member: 76 years old, 7+ chronic conditions, nursing-home eligible
-- PACE has operated since the 1970s (On Lok in San Francisco)
-- PACE serves 0.13% of 67M Medicare-eligible population
+- PACE market concentration: nearly half of enrollees served by 10 largest parent organizations
+- PACE geographic concentration: over 50% of enrollees in California, New York, Pennsylvania
+- Only 13 states have 1,000+ PACE enrollees
 - Most PACE parent organizations operate single program in one state
+- PACE eligibility: 55+ years old, needing nursing home-level care, Medicare + Medicaid status
+- PACE model: single provider and payer for 100% of member's medical, social, and psychiatric needs, entirely replaces Medicare and Medicaid cards

inbox/archive/2025-04-22-futardio-proposal-testing-v03-transfer.md

@@ -6,9 +6,12 @@ url: "https://www.futard.io/proposal/2dvNKyxKzVuUMcd89wzfuYjX2RKbJps2Srqu4mJ7LEg
 date: 2025-04-22
 domain: internet-finance
 format: data
-status: unprocessed
+status: enrichment
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
+processed_by: rio
+processed_date: 2026-03-15
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Proposal Details
@@ -48,3 +51,14 @@ This would be the test example for transferring the MetaDAO treasury of USDC to
 - Autocrat version: 0.3
 - Completed: 2025-04-22
 - Ended: 2025-04-22
+
+
+## Key Facts
+- Test DAO proposal 'Testing v0.3 Transfer' passed on 2025-04-22
+- Proposal aimed to transfer MetaDAO treasury USDC to v0.4 DAO
+- Proposal account: 2dvNKyxKzVuUMcd89wzfuYjX2RKbJps2Srqu4mJ7LEgC
+- Proposal number: 1
+- DAO account: GCSGFCRfCRQDbqtPLa6bV7DCJz26NkejR182or8PNqRw
+- Proposer: 8Cwx4yR2sFAC5Pdx2NgGHxCk1gJrtSTxJoyqVonqndhq
+- Autocrat version: 0.3
+- Proposal completed and ended: 2025-04-22

inbox/archive/2025-06-01-cell-med-glp1-societal-implications-obesity.md

@@ -7,9 +7,13 @@ date: 2025-06-01
 domain: health
 secondary_domains: [entertainment, internet-finance]
 format: paper
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, obesity, societal-impact, equity, food-systems, population-health, sustainability]
+processed_by: vida
+processed_date: 2026-03-15
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md", "the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -52,3 +56,11 @@ EXTRACTION HINT: Focus on both the population-level effect AND the equity concer
 
 flagged_for_clay: ["GLP-1 adoption is reshaping cultural narratives around obesity, body image, and pharmaceutical solutions to behavioral problems — connects to health narrative infrastructure"]
 flagged_for_rio: ["GLP-1 equity gap creates investment opportunity in access-focused models that serve underserved populations — potential Living Capital thesis"]
+
+
+## Key Facts
+- October 2025 Gallup poll: 12.4% of US adults taking GLP-1 for weight loss (30M+ people)
+- US obesity prevalence: 39.9% (2022) → 37.0% (2025), representing 7.6M fewer obese Americans
+- WHO issued conditional recommendations for GLP-1s in December 2025
+- Obesity costs US $400B+ annually
+- WHO three-pillar approach: healthier environments (population policy), protect high-risk individuals, person-centered care